In 2012, Park et al. suggested that XRCC2 is associated with elevated breast cancer risk based on finding six pathogenic coding variants in 1308 women with early-onset breast cancer from Europe, North America, and Australia and no variant in 1120 controls (p < 0.02) [13]. Here, XRCC2 is linked to breast carcinoma.